ரோச் பார்மா இந்தியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ரோச் பார்மா இந்தியா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ரோச் பார்மா இந்தியா Today - Breaking & Trending Today

Roche's antibody Covid drug now available in India; does Cipla drug work and pricing


Karnataka sets 24-hr deadline for Cipla, Jubilant to supply Remdesivir
Roche India on Monday announced the rollout of its first batch of the antibody cocktail (Casirivimab and Imdevimab) against Coronavirus in India. The cocktail drug will be marketed by Cipla pan-India.
The second batch of the cocktail jabs will be made available by mid-June. Together, they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients, the company said in a statement.
The price for each patient dose [a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750. The maximum retail price for the multi-dose pack (each pack can treat two patients) is Rs 119,500, the statement added. ....

V Simpson Emmanuel , Umang Vohra , Casirivimab Imdevimab , Central Drugs Standards Control Organisation , Representational Picture , Managing Director , Roche Pharma India , Emergency Use Authorisation , வ் சிம்ப்சன் இம்மானுவேல் , உமங் வோஹ்ரா , மைய மருந்துகள் தரநிலைகள் கட்டுப்பாடு ஆர்கநைஸேஶந் , நிர்வகித்தல் இயக்குனர் , ரோச் பார்மா இந்தியா ,

Roche's antibody Covid drug now available in India


Roche s antibody Covid drug now available in India
​ By
IANS
|
​ 0 Views
Roche s antibody Covid drug now available in India. Image Source: IANS News
Mumbai, May 24 : Roche India on Monday announced the rollout of its first batch of the antibody cocktail (Casirivimab and Imdevimab) against Coronavirus in India. The cocktail drug will be marketed by Cipla pan-India.
The second batch of the cocktail jabs will be made available by mid-June. Together, they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients, the company said in a statement.
The price for each patient dose [a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750. The maximum retail price for the multi-dose pack (each pack can treat two patients) is Rs 119,500, the statement added. ....

V Simpson Emmanuel , Umang Vohra , Casirivimab Imdevimab , Central Drugs Standards Control Organisation , Roche India , Managing Director , Roche Pharma India , Emergency Use Authorisation , வ் சிம்ப்சன் இம்மானுவேல் , உமங் வோஹ்ரா , மைய மருந்துகள் தரநிலைகள் கட்டுப்பாடு ஆர்கநைஸேஶந் , ரோச் இந்தியா , நிர்வகித்தல் இயக்குனர் , ரோச் பார்மா இந்தியா ,